Bayer Buys Marketing Rights to GW Pharmaceuticals’ Cannabis-Based Treatment
By Business Review Editor
Pharma Deals Review: Vol 2003 Issue 37 (Table of Contents)
Published: 3 Jun-2003
DOI: 10.3833/pdr.v2003.i37.899 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Bayer entered into an agreement with GW Pharmaceuticals to acquire exclusive US marketing rights to GW’s cannabis-based medicine, Sativex® for the pain-relief treatment for multiple sclerosis...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS